Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$1.66 - $2.31 $123,547 - $171,924
74,426 Added 26.05%
360,091 $799,000
Q2 2023

Aug 14, 2023

BUY
$1.61 - $1.96 $62,435 - $76,008
38,780 Added 15.71%
285,665 $531,000
Q1 2023

May 15, 2023

BUY
$1.8 - $2.83 $135,993 - $213,812
75,552 Added 44.1%
246,885 $478,000
Q4 2022

Feb 13, 2023

BUY
$2.05 - $5.5 $178,608 - $479,193
87,126 Added 103.47%
171,333 $421,000
Q3 2022

Nov 14, 2022

BUY
$0.94 - $5.99 $9,511 - $60,612
10,119 Added 13.66%
84,207 $417,000
Q2 2022

Aug 11, 2022

BUY
$3.2 - $5.69 $237,081 - $421,560
74,088 New
74,088 $347,000

Others Institutions Holding EQRX

About EQRx, Inc.


  • Ticker EQRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 448,140,992
  • Description
  • EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...
More about EQRX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.